Hepatotoxicity of Antituberculosis Therapy (HAT) Study
NCT04159441 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2019-11-12
Summary
Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.
Conditions
- Chemical and Drug Induced Liver Injury
Interventions
- OTHER
-
None intervetion
None intervetion
Sponsors & Collaborators
-
Huashan Hospital
lead OTHER
Principal Investigators
-
Wenhong Zhang · Huashan Hospital
-
Yongguo LI · First Affiliated Hospital of Harbin Medical University
-
Dapeng Bai · Haihe Hospital in Tianjin
-
Meiying Wu · The Fifth Hospital in Suzhou
-
Huaicheng Wang · Third People's Hospital in Changzhou
-
Qinfang Ou · Fifth Hospital in Wuxi
-
Yonglan Pu · First People's Hospital in Taicang
-
Fan Xia · The 905th Hospital of the PLA Navy
-
Yuanyuan Chen · Red Cross Hospital, Hangzhou, China
-
Zumo Zhou · People's Hospital in Zhuji
-
Xiaohong Chen · Fuzhou Pulmonary Hospital in Fujian
-
Guofang Deng · The Third People's Hospital in Shenzhen
-
Shiwu Ma · People's Liberation Army Joint Service Support Unit 920 Hospital (formerly Kunming General Hospital of Chengdu Military Region)
-
Youfang Gao · People's Hospital in Haozhou
-
Yongfang Jiang · Central South University Xiangya Second Hospital
-
Hongying Yu · Huaihua First People Hospital in Hunan
-
Bo Chen · Longtan Hospital in Guangxi
-
Weiqiang Zheng · Guangdong Medical University Affiliated Hospital
-
Liyuan Zhang · The Second Affiliated Hospital of Hainan Medical College
-
Guanghui Xu · Tuberculosis Control Center in Jiangmen
-
Anjie Zhang · Yubei Second People's Hospital
-
Hancheng Liang · The Sixth People's Hospital in Dongguan
-
Yuqing Wu · Chest Hospital in Jiangxi
-
Xilin Zhang · The Forth People's Hospital in Foshan
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-05
- Primary Completion
- 2020-12-05
- Completion
- 2021-06-05
More Related Trials
-
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
NCT06539455 ·Status: ACTIVE_NOT_RECRUITING
-
Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis
NCT06484530 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
NCT01677871 ·Status: UNKNOWN ·Phase: NA
-
A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients
NCT06021041 ·Status: UNKNOWN
-
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
NCT05401071 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity
NCT00929786 ·Status: COMPLETED
-
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
NCT01364324 ·Status: COMPLETED
-
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
NCT04421495 ·Status: UNKNOWN ·Phase: PHASE4
-
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
NCT00834353 ·Status: COMPLETED
-
Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs
NCT00979290 ·Status: COMPLETED
-
The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study
NCT01182259 ·Status: UNKNOWN
-
Tuberculosis Drug Levels in Diabetics
NCT04242511 ·Status: UNKNOWN
-
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
NCT02467608 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Tuberculosis in China
NCT01071603 ·Status: COMPLETED
-
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
NCT03211208 ·Status: COMPLETED
-
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
NCT04655794 ·Status: UNKNOWN
-
Determining Risk in Latent Tuberculosis
NCT01571739 ·Status: TERMINATED
-
The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)
NCT02889757 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Intravenous Treatment of Tuberculosis
NCT04150367 ·Status: TERMINATED
-
Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
NCT01395654 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Weight and/or Obesity on Ethambutol Drug Concentrations
NCT01048697 ·Status: COMPLETED ·Phase: PHASE4
-
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
NCT04094012 ·Status: COMPLETED ·Phase: PHASE3
-
Tuberculosis Drug Levels and Continuous Glucose Monitoring in Diabetic Patients
NCT05329415 ·Status: UNKNOWN
-
Asymptomatic TB With Innovative Modified Short-course Regimens
NCT06153069 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
NCT02430259 ·Status: COMPLETED ·Phase: PHASE3